Vaccines for preventing typhoid fever (Q24201238)

5

0 references

Abigail Fraser

object named as

Abigail Fraser

3

0 references

Elad Goldberg

2

object named as

Elad Goldberg

0 references

Camilo J Acosta

4

object named as

Camilo J Acosta

0 references

author name string

Elspeth Anwar

Cochrane Database of Systematic Reviews

1

0 references

publication date

2 January 2014

0 references

published in

0 references

cites work

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Impact of Vi vaccination on spatial patterns of typhoid fever in the slums of Kolkata, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A seven-year field trial of two typhoid vaccines in Guyana

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Safety and efficacy of combined meningococcal and typhoid vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Typhoid and paratyphoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Impact of age and drug resistance on mortality in typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Global trends in typhoid and paratyphoid Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A study of typhoid fever in five Asian countries: disease burden and implications for controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

The use of typhoid vaccines in Asia: the DOMI experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Typhoid fever in Bangladesh: implications for vaccination policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Typhoid fever in children aged less than 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Vaccines for preventing typhoid fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Vaccines for preventing typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

A first step in bringing typhoid fever out of the closet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

7 January 2021

Immunogenicity of Salmonella typhi Ty21a vaccine for young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

7 January 2021

Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

7 January 2021

Typhoid Vi: a less reactogenic vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

7 January 2021

Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB3

7 January 2021

10.1002/14651858.CD001261.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

24385413

1 reference

Consolidated OpenCitations Corpus – April 2017